Ring Therapeutics Valuation, Funding & Investors

SmartCella is a Milan-based biotechnology company advancing cell therapy delivery for cardiac regeneration. Its SmartCella device enables precise intracoronary injection of stem cells, drugs, and RNA therapeutics during procedures. Tested in preclinical models for heart failure and myocardial infarction, it partners with clinics in Italy and the EU. Founded in 2016, SmartCella focuses on interventional cardiology applications.

Strand Therapeutics is a Cambridge-headquartered biotechnology firm founded in 2017 that engineers programmable mRNA medicines using synthetic biology principles. The platform deploys logic circuits within cells to detect tumor-specific signals and produce cancer-fighting proteins on demand, such as cytokines for immunotherapy. Their lead candidates target solid tumors including glioblastoma and head-and-neck cancers through intravenous administration. Strand Therapeutics collaborates with academic institutions like MIT and has progressed multiple programs into preclinical testing for oncology applications.

Ocumension Therapeutics is an ophthalmic pharmaceutical platform company identifying, developing, and commercializing ophthalmic therapies. It provides a pharmaceutical total solution to address unmet ophthalmic medical needs in China. Its product candidates include OT-401 (YUTIQ), OT-101, OT-301 (NCX 470), OT-1001 (ZERVIATE), OT-502 (DEXYCU), OT-202, OT-503 (NCX 4251), OT-701, Ou Qin, Brimonidine tartrate eye drop, 0.5% moxifloxacin eye drop, OT-601-C, OT-302, OT-1301, T-1601, and OT-1602.

Expedition Therapeutics is a San Diego-headquartered clinical-stage biotech developing oral therapies for inflammatory respiratory diseases. Its lead candidate, EXPD-101, inhibits dipeptidyl peptidase 1 to reduce neutrophilic inflammation in chronic obstructive pulmonary disease and bronchiectasis. The company completed Phase 1 trials in 2023 and plans Phase 2 studies in 2024 across Europe and North America. Expedition in-licenses assets while building internal pipelines, supported by a team from GSK and AstraZeneca. It operates R&D facilities in La Jolla, California.

Shoreline Biosciences is a biotechnology company developing allogeneic, off-the-shelf cellular immunotherapies for cancer, using induced pluripotent stem cells (iPSCs) to derive natural killer cell and macrophage therapies for solid tumors and blood cancers. Founded in 2020 by Kleanthis Xanthopoulos and based in San Diego, the company builds smart manufacturing capabilities to support its pipeline and holds strategic partnerships with Kite, a Gilead company, and BeiGene for cell therapy development.

MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, it sells allografts for ophthalmic surgery and dental applications through licenses to third parties.

Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.

Ollin Biosciences is an Austin, Texas-based clinical-stage biopharmaceutical company that acquires and develops bispecific antibody therapies for vision-threatening eye diseases rather than pursuing in-house drug discovery. Its lead candidate, OLN324, is a VEGF/Ang2 bispecific antibody licensed from China's Innovent Biologics that is advancing toward Phase 3 trials for diabetic macular edema and wet age-related macular degeneration. A second program, OLN102, licensed from VelaVigo, is a TSHR/IGF-1R bispecific antibody in development for thyroid eye disease and Graves' disease.

Yantai Lannacheng Biotechnology is a Yantai-based biotechnology company that develops class I integrated platforms for diagnosis and therapy using novel nuclear radiopharmaceuticals targeting tumors. The firm advances research in targeted radionuclide therapies and diagnostic agents for oncology applications. Its platform supports development of precision medicines for cancer treatment in China.

Umoja Biopharma engineers in vivo CAR T-cell therapies that reprogram patients' T cells to attack solid tumors and hematological malignancies resistant to existing treatments. Seattle-headquartered, the company advances its AlloVector platform for localized immune cell activation without ex vivo manipulation. Partnerships with Biogen and Takeda support clinical progression in oncology pipelines targeting glioblastoma and other cancers.

AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Its product candidates are designed to target established pathways and utilize validated modalities, with a focus on addressing limitations associated with prior treatment approaches. The company's pipeline includes small molecule and antibody product candidates aimed at targets associated with fibrotic diseases. Key candidates include Ontunisertib (AGMB-129) and AGMB-447.

Alpha Biopharma is a Shanghai-headquartered clinical-stage biopharmaceutical company advancing innovative drugs in oncology, immunology, and metabolic diseases. The firm conducts global trials in partnership with CROs and in-licenses assets from international developers, maintaining R&D facilities in China and the US.

Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.

Medrobotics is a medical robotics firm commercializing the Flex Robotic System, a steerable and shapeable endoscopic platform. The system enables minimally invasive access to complex anatomies like the throat, lung, and prostate through a single small incision, surpassing rigid tool limitations.

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.

Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.

Elpiscience Biopharmaceuticals is a Shanghai-headquartered clinical-stage biopharmaceutical company developing bispecific antibodies and multispecific therapeutics for immuno-oncology. Its pipeline includes ES101, a CCR8-targeting antibody in Phase I trials across China and the United States, alongside candidates targeting TIGIT, CD47, and PD-L1. Established in 2017, the company advances novel molecules addressing tumor microenvironment mechanisms to treat solid tumors. Elpiscience collaborates with international partners like Fosun Pharma and maintains research sites in Shanghai and Suzhou.

Iambic is a San Francisco-based therapeutics company employing AI to accelerate drug discovery. Its platform integrates Enchant, a multi-modal transformer for early clinical outcome prediction, and NeuralPLexer for protein-ligand structure forecasting. By embedding physics into AI models, Iambic explores vast chemical spaces to target challenging proteins, optimize therapeutic profiles, and conduct weekly design-make-test cycles through automated labs. The company raised $15 million in seed funding in 2022.